• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
NF-kB Pathway / Related Products
You are here: Product Lines > DNA Regulation / Transcription > Transcription Factors / Related Products > NF-kB Pathway / Related Products
 
Toolbar - View Selection
 
 Items 100-120 of 129 Page 6 of 7 Select Page: << 1 2 3 4 5 6 7  >>  
ALX-210-462 Revised 10-Apr-08
Polyclonal Antibody to TRB-3 (human)
Add to Clipboard
SYNONYMS anti-Tribbles Homolog 3 (human) PAb
anti-Neuronal Cell Death-inducible Putative Kinase (human) PAb
anti-p65-interacting Inhibitor of NF-κB (human) PAb
anti-SINK (human) PAb
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY NF-kB Pathway Modulators
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-210-462-C100   100 µg 310.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
SOURCE/HOST: From rabbit.
CONCENTRATION: 1mg/ml.
PURITY DETAIL: Purified IgG.
FORMULATION: Liquid. In PBS, pH 7.4. Contains no preservatives.
IMMUNOGEN: Synthetic peptide corresponding to aa 112-125 (A112RLPPHKHVARPTE125) of human TRB-3 (tribbles homolog 3).
SPECIFICITY: Recognizes human TRB-3.
APPLICATION: ELISA (direct and indirect: 1:2’000-1:5’000)
Immunohistochemistry (paraffin sections(1:500))
Western Blot (1:2’000-1:5’000 using ECL. Suggested blocking and dilution buffer is PBST containing 0.05% Tween 20 and 5% skim milk. Suggested incubation time is 1 hour at room temperature).
Optimal conditions must be determined individually for each application.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for 1-2 weeks when stored at +4°C.
HANDLING: After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Product Images
Please click on thumbnails to enlarge.
General Information
Tribbles homolog 3 (TRB-3) is a pseudokinase, shown to act as a potent negative regulator of PPARγ, a master regulator of adipocyte differentiation, and to control adipogenesis.
MANUFACTURER Manufactured by AdipoGen, Inc.
Further Categories Containing This Product:
PPAR Other Products • PI(3)K-Akt-mTOR Pathway Other Products • MAPK Pathway Other Products • Transcription Regulators Other Products • Polyclonal Antibodies
 
 
ALX-210-939 Revised 11-May-07
Polyclonal Antibody to ZUD (AT116)
Add to Clipboard
SYNONYMS anti-ZU5 and Death Domain-containing Inhibitor of NF-κB PAb (AT116)
anti-Unc-5 Homolog C (C. elegans)-like PAb (AT116)
anti-UNC5CL PAb (AT116)
PRODUCT LINE Cell Death / Apoptosis / Autophagy
PRODUCT CATEGORY Netrins & Receptors / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-210-939-C100   100 µg 380.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Mouse
SOURCE/HOST: From rabbit.
CONCENTRATION: 1mg/ml
PURITY DETAIL: Protein A-affinity purified.
FORMULATION: Liquid. In PBS containing 0.02% sodium azide.
IMMUNOGEN: Recombinant human ZUD domain (aa 402-518).
SPECIFICITY: Recognizes human and mouse ZUD.
APPLICATION: Immunocytochemistry (1:100)
Immunoprecipitation (1:200)
Western Blot (1:1’000)
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 1 year after receipt when stored at -20°C.
HANDLING: Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
General Information
ZUD is cytoplasmic protein with a ZU5 and death domain. It interacts with the NF-κB subunit p105 and transactivator p65 and inhibits NF-κB -dependent transcription when its overexpressed. ZUD seems to be a inhibitor of NF-κB signalling, and enhance cell death to apoptotic stimuli like TNF and TRAIL.
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
Identification of a ZU5 and death domain-containing inhibitor of NF-kappaB: J. Zhang, et al.; J. Biol. Chem. 279, 17819 (2004) Abstract; Full Text
Further Categories Containing This Product:
TNF & TNF Receptor Superfamily Other Products • TRAIL & TRAIL Receptors Other Products • Polyclonal Antibodies • NF-kB Pathway Inhibitors
 
 
ALX-210-481 Revised 13-Feb-08
Polyclonal Antibody to Ribosomal Protein S3 (human)
Add to Clipboard
SYNONYMS anti-RPS3 (human) PAb
anti-40S Ribosomal Protein S3 (human) PAb
anti-IMR-90 Ribosomal Protein S3 (human) PAb
PRODUCT LINE Protein Synthesis, Modification & Degradation
PRODUCT CATEGORY Ribosomal Proteins / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-210-481-C100   100 µg 410.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
SOURCE/HOST: From rabbit.
CONCENTRATION: 1mg/ml.
PURITY DETAIL: Purified IgG.
FORMULATION: Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.
IMMUNOGEN: Recombinant human ribosomal protein S3.
SPECIFICITY: Recognizes human ribosomal protein S3.
APPLICATION: ELISA (direct and indirect: 1:2’000-1:5’000)
Immunoprecipitation (1:500-1:5’000)
Western Blot (1:500-1:5’000 using ECL. Suggested blocking and dilution buffer is PBST containing 0.05% Tween 20 and 5% skim milk. Suggested incubation time is 1 hour at room temperature).
Optimal conditions must be determined individually for each application.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for 1-2 weeks when stored at +4°C.
HANDLING: Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
Product Images
Please click on thumbnails to enlarge.
Product Specific Literature References
Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation: T.S. Kim, et al.; Mol. Biol. Cell 17, 824 (2006) Abstract; Full Text
Reduction of invasion in human fibrosarcoma cells by ribosomal protein S3 in conjunction with Nm23-H1 and ERK: S.H. Kim & J. Kim; Biochim. Biophys. Acta 1763, 823 (2006) Abstract
Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation: F. Wan, et al.; Cell 131, 927 (2007) Abstract
General Information
MANUFACTURER Manufactured by AdipoGen, Inc.
Related Products
Further Categories Containing This Product:
Co-Chaperones & HSP-interacting Proteins / Related Products • DNA Endonucleases / Related Products • NF-kB Pathway Other Products • MAPK Pathway Other Products • Polyclonal Antibodies
 
 
ALX-840-609 Revised 03-May-07
Positive Control (Cell Lysate) for Antibodies to RIG-I (human)
Add to Clipboard
SYNONYMS Positive Control (Cell Lysate) for Antibodies to RIG-1 (human)
Positive Control (Cell Lysate) for Antibodies to Retinoic Acid-inducible Gene 1 (human)
Positive Control (Cell Lysate) for Antibodies to DEAD-box Protein 58 (human)
Positive Control (Cell Lysate) for Antibodies to Probable ATP-dependent RNA Helicase DDX58 (human)
PRODUCT LINE Immunology
PRODUCT CATEGORY Positive Controls (Cell Lysates & Extracts)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-840-609-R100   100 µl 70.00 USD Add To Cart
Product Specification
SOURCE/HOST: Whole cell lysate of HEK293T cells transfected with an expression plasmid for human RIG-I (aa 1-925).
QUANTITY: 100µl corresponding to 2x105 cells.
PURITY: ≥95%
FORMULATION: Liquid. In 5x sample buffer (312.5mM TRIS, pH 6.8, containing 10% SDS, 6% glycerol, 0.075% bromophenol blue, 10% β-mercaptoethanol and 10mM DTT).
APPLICATION: Positive control in Western blot for MAb to RIG-I (human) (Alme-1)
(ALX-804-849) and PAb to RIG-I (human) (AT111) (Prod. No. ALX-210-932). Add 13µl sterile water and 2µl DTT (100mM) to 5µl of cell lysate.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
General Information
MANUFACTURER Manufactured by Apotech Corporation.
Related Products
Further Categories Containing This Product:
NF-kB Pathway Other Products • Caspase Recruitment Domain [CARD] Proteins / Related Products
 
 
ALX-270-458 Revised 15-Jan-08
PPM-18
Add to Clipboard
SYNONYMS 2-Benzoylamino-1,4-naphthoquinone
PRODUCT LINE Nitric Oxide Pathway
PRODUCT CATEGORY NOS Inhibitors (NOS Induction & Enzyme Activity)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-458-M010   10 mg 140.00 USD Add To Cart
Product Specification
FORMULA: C17H11NO3
MW: 277.3
CAS NUMBER: 65240-86-0
PURITY: ≥97% (HPLC)
APPEARANCE: Yellow to orange solid.
SOLUBILITY: Soluble in DMSO or acetonitrile.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY:

Stable for at least 3 years after receipt when stored at -20°C.
HANDLING: Packaged under inert gas. Protect from light. After reconstitution, prepare aliquots and store at -20°C.

Product Description
Cell permeable, anti-inflammatory agent that inhibits expression of iNOS (NOS II) (IC50~5mM). Blocks activation of NF-κB in vitro and in vivo. Does not directly affect enzymatic activities of iNOS (NOS II) or eNOS (NOS III).
Product Specific Literature References
Synthesis and antiplatelet, antiinflammatory and antiallergic activities of 2,3-disubstituted 1,4-naphthoquinones: J.C. Lien, et al.; Chem. Pharm. Bull. (Tokyo) 44, 1181 (1996) Abstract
Inhibition of nitric oxide synthase expression by PPM-18, a novel anti-inflammatory agent, in vitro and in vivo: S.M. Yu, et al.; Biochem. J. 328, 363 (1997) Abstract; Full Text
Shear stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor kappaB binding: M.E. Davis, et al.; J. Biol. Chem. 279, 163 (2004) Abstract; Full Text
Further Categories Containing This Product:
NF-kB Pathway Modulators • Anti-inflammatory Agents Other Products
 
 
ALX-400-002 Revised 15-May-08
Pyrrolidinedithiocarbamic acid . ammonium salt
Add to Clipboard
SYNONYMS Ammoniumpyrrolidinedithiocarbamate
Ammoniumtetramethylenedithiocarbamate
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY NF-kB Pathway Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-400-002-G005   5 g 29.00 USD Add To Cart
ALX-400-002-G025   25 g 55.00 USD Add To Cart
Product Specification
FORMULA: C5H8NS2 . NH4
MW: 146.3 . 18.0
CAS NUMBER: 5108-96-3
PURITY: ≥98%
APPEARANCE: White to-off white solid.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HAZARD: IRRITANT.

Product Description
Inhibitor of NF-κB activation (induced by either PMA or TNF-α) in various cell types.
Product Specific Literature References
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells: R. Schreck, et al.; J. Exp. Med. 175, 1181 (1992) Abstract
Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes: H.W. Ziegler-Heitbrock, et al.; J. Immunol. 151, 6986 (1993) Abstract
Pyrrolidine dithiocarbamate inhibits induction of nitric oxide synthase activity in rat alveolar macrophages: M.P. Sherman, et al.; BBRC 191, 1301 (1993) Abstract
Pyrrolidine dithiocarbamate differentially affects interleukin 1 beta- and cAMP-induced nitric oxide synthase expression in rat renal mesangial cells: W. Eberhardt, et al.; BBRC 200, 163 (1994) Abstract
In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation: T.S. Blackwell, et al.; Immunol. 157, 1630 (1996) Abstract
In vivo inhibition of nuclear factor-kappa B activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock: S.F. Liu, et al.; J. Immunol. 159, 3976 (1997) Abstract
Zinc is required in pyrrolidine dithiocarbamate inhibition of NF-kappaB activation: C.H. Kim, et al.; FEBS Lett. 449, 28 (1999) Abstract
Dual activity of pyrrolidine dithiocarbamate on kappa B-dependent gene expression in U937 cells: I. Regulation by the phorbol ester TPA: K. Watanabe, et al.; Cell Signal 11, 479 (1999) Abstract
Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes: S.F. Liu, et al.; Circulation 100, 1330 (1999) Abstract
Dual activity of pyrrolidine dithiocarbamate on kappaB-dependent gene expression in U937 cells: II. Regulation by tumour necrosis factor- alpha: K. Watanabe, et al.; Cell Signal 11, 371 (1999) Abstract
Pyrrolidine dithiocarbamate inhibits TNF-alpha-dependent activation of NF-kappaB by increasing intracellular copper level in human aortic smooth muscle cells: A. Iseki, et al.; Biochem Biophys Res Commun 276, 88 (2000) Abstract
 
 
ALX-420-038 Revised 09-May-07
R-848
Add to Clipboard
SYNONYMS 4-Amino-2-(ethoxymethyl)-a,a-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol
S 28463
Resiquimod
PRODUCT LINE Immunology
PRODUCT CATEGORY Immunomodulators Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-420-038-M005   5 mg 50.00 USD Add To Cart
ALX-420-038-M025   25 mg 200.00 USD Add To Cart
Product Specification
FORMULA: C17H22N4O2
MW: 314.4
CAS NUMBER: 144875-48-9
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO, 100% methanol or 5% methanol in dichloromethane. Poorly soluble in acetonitrile or ethyl acetate.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Selective ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human. Potent antitumor and antiviral compound. Stimulates antibody secretion, cytokine production, protection from apoptosis and CD80 upregulation.
Product Specific Literature References
The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001) Abstract
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002) Abstract
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002) Abstract
Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses: J.J. Wu, et al.; Antiviral Res. 64, 79 (2004) Abstract
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005) Abstract
Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells: G. Caron, et al.; J. Immunol. 175, 1551 (2005) Abstract; Full Text
Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848): M.J. McCluskie, et al.; Antiviral Res. 69, 77 (2006) Abstract
Further Categories Containing This Product:
CD40 & CD40L [CD154] / Related Products • Inflammasome • TLR Agonists Other Products
 
 
ALX-380-092 Revised 03-Jul-08
Radicicol
Add to Clipboard
SYNONYMS Monorden
1aS-(1aR*,2Z,4E,14*,15aR*)]-8-Chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Antifungal
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-092-M001   1 mg 75.00 USD Add To Cart
ALX-380-092-M005   5 mg 295.00 USD Add To Cart
Product Specification
FORMULA: C18H17ClO6
MW: 364.8
CAS NUMBER: 12772-57-5
MERCK INDEX: 14: 6253
RTECS: RR1105000
SOURCE/HOST: Isolated from Humicola fuscoatra.
PURITY: ≥98% (HPLC)
APPEARANCE: White to light yellow powder.
SOLUBILITY: Soluble in DMSO, methanol or acetone.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.
HAZARD: MAY BE CARCINOGENIC. HARMFUL.

Product Description
Antifungal macrocyclic lactone antibiotic with antimalarial activity. Potent inhibitor of HSP90. Binds more strongly to HSP90 (nanomolar affinity) than to Grp94. Also binds to yeast HSP90, E. coli HtpG and TRAP-1. Non-competitive inhibitor of ATP citrate lyase. Anti-angiogenic. Specifically inhibits the interaction between HIF-1α/Arnt heterodimer and the hypoxia-responsive element (HRE), reducing VEGF expression. Protein tyrosine kinase inhibitor, e.g. p60v-src (IC50=0.27nM). Inhibitor of cyclooxygenase-2 (COX-2) expression (IC50=27nM) without affecting COX-1 expression in LPS-stimulated macrophages. Induces the differentiation of HL-60 cells into macrophages, blocking cell cycle at G1 and G2. Suppressor of NIH 3T3 cell transformation by diverse oncogenes such as mos, ras and src in part by blocking the key signal transduction intermediates such as MAP kinase and GAP-associated p62. Inhibitor of AP-1-, NF-κB- and serum response factor (SRF)-mediated transcription (e.g. expression of iNOS). Represses the transcriptional function of the estrogen receptor. Inhibits archeal growth and DNA topoisomerase VI (a Topo IIB family topoisomerase). Blocks replication of negative-strand RNA viruses.
Product Specific Literature References
Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol: H.J. Kwon, et al.; Cancer Res. 52, 6926 (1992) Abstract
Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis: T. Oikawa, et al.; Eur. J. Pharmacol. 241, 221 (1993) Abstract
Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis: P. Chanmugam, et al.; J. Biol. Chem. 270, 5418 (1995) Abstract; Full Text
Suppression of RAS and MOS transformation by radicicol: J.F. Zhao, et al.; Oncogene 11, 161 (1995) Abstract
Induction of differentiation of HL-60 cells by the anti-fungal antibiotic, radicicol: Y. Shimada, et al.; J. Antibiot. 48, 824 (1995) Abstract
Radicicol inhibits tyrosine phosphorylation of the mitotic Src substrate Sam68 and retards subsequent exit from mitosis of Src-transformed cells: I. Pillay, et al.; Cell Growth Differ. 7, 1487 (1996) Abstract
Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway: S. Soga, et al.; J. Biol. Chem. 273, 822 (1998) Abstract; Full Text
Antimalarial activity of radicicol, heptelidic acid and other fungal metabolites: Y. Tanaka, et al.; J. Antibiot. 51, 153 (1998) Abstract
Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol: S.V. Sharma, et al.; Oncogene 16, 2369 (1998) Abstract
Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin: S.M. Roe, et al.; J. Med. Chem. 42, 260 (1999) Abstract
T.W. Schulte, et al.; Mol. Endocrinol. 13, 1435 (1999) Abstract; Full Text
Radicicol suppresses expression of inducible nitric-oxide synthase by blocking p38 kinase and nuclear factor-kappaB/Rel in lipopolysaccharide-stimulated macrophages: Y.J. Jeon, et al.; J. Pharmacol. Exp. Ther. 294, 548 (2000) Abstract; Full Text
Radicicol binds and inhibits mammalian ATP citrate lyase: S.W. Ki, et al.; J. Biol. Chem. 275, 39231 (2000) Abstract; Full Text
Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade: P.N. Kim, et al.; Cell Growth Differ. 12, 543 (2001) Abstract; Full Text
Radicicol-sensitive peptide binding to the N-terminal portion of GRP94: S. Vogen, et al.; J. Biol. Chem. 277, 40742 (2002) Abstract; Full Text
Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol: E. Hur, et al.; Mol. Pharmacol. 62, 975 (2002) Abstract; Full Text
Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90: M.O. Lee, et al.; Mol. Cell Endocrinol. 188, 47 (2002) Abstract
Development of radicicol analogues: S. Soga, et al.; Curr. Cancer Drug Targets 3, 359 (2003) Abstract
Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor: K. Harashima, et al.; Int. J. Radiat. Biol. 81, 63 (2005) Abstract
Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol: D. Gadelle, et al.; Nucleic Acid Res. 33, 2310 (2005) Abstract
Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site: M.K. Hadden, et al.; Curr. Top. Med. Chem. 6, 1173 (2006), Review Abstract
The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?: C.R. Barker, et al.; Int. J. Cancer 118, 2685 (2006) Abstract
Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol: K.D. Corbett & J.M. Berger; Nucleic Acids Res. 34, 4269 (2006) Abstract
Chemistry and biology of resorcylic acid lactones: N. Winssinger & S. Barluenga; Chem. Commun. (Camb.) 22 (2007) Abstract
Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses: J.H. Connor, et al.; Virology 362, 109 (2007) Abstract
Further Categories Containing This Product:
Tyrosine Kinase Inhibitors • Cell Cycle Blockers & Inhibitors / Related Products • Estrogen & Estrogen Receptors / Related Products • Antibiotics - Nitric Oxide Pathway Modulators • Antitumor Agents (Hormone-related) • NF-kB Pathway Inhibitors • Malaria / Related Products • Antibiotics - Antimalarial • Antibiotics - Protein Kinase Inhibitors • Antibiotics - NF-kB Inhibitors •